Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?

The company has too many weapons at its disposal.Developing brand-new drugs is a long and expensive process that doesn't always deliver a positive return on investment. Occasionally, some pharmaceutical companies hit the jackpot and launch medicines worth all that trouble. That's what Eli Lilly (LLY -0.55%) has on its hands with tirzepatide, marketed as Mounjaro in the diabetes market and as Zepbound to help with weight loss. Analysts predict that tirzepatide's peak sales could reach $25 billion, but to get ...